Page last updated: 2024-11-08

noscapine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Noscapine: A naturally occurring opium alkaloid that is a centrally acting antitussive agent. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

(-)-noscapine : A benzylisoquinoline alkaloid that is 1,2,3,4-tetrahydroisoquinoline which is substituted by a 4,5-dimethoxy-3-oxo-1,3-dihydro-2-benzofuran-1-yl group at position 1, a methylenedioxy group at positions 6-7 and a methoxy group at position 8. Obtained from plants of the Papaveraceae family, it lacks significant painkilling properties and is primarily used for its antitussive (cough-suppressing) effects. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
PapaveraceaefamilyThe poppy plant family of the order Papaverales, subclass Magnoliidae, class Magnoliopsida. These have bisexual, regular, cup-shaped flowers with one superior pistil and many stamens; 2 or 3 conspicuous, separate sepals and a number of separate petals. The fruit is a capsule. Leaves are usually deeply cut or divided into leaflets.[MeSH]PapaveraceaeThe poppy plant family of the order Papaverales, subclass Magnoliidae, class Magnoliopsida. These have bisexual, regular, cup-shaped flowers with one superior pistil and many stamens; 2 or 3 conspicuous, separate sepals and a number of separate petals. The fruit is a capsule. Leaves are usually deeply cut or divided into leaflets.[MeSH]

Cross-References

ID SourceID
PubMed CID275196
CHEMBL ID364713
CHEBI ID73237
SCHEMBL ID4559
MeSH IDM0015008

Synonyms (174)

Synonym
AC-20272
BRD-K89237706-001-03-8
(3s)-6,7-dimethoxy-3-[(5r)-4-methoxy-6-methyl-7,8-dihydro-5h-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3h-2-benzofuran-1-one
nsc121869
nsc-121869
.beta.-narcotine
nectadon
nsc5366 ,
narkotin
narcotin
narcotussin
1-.alpha.-narcotine
wln: t c566 do fo kn eh & & tj ho1 k1 j-dt56 bvo dhj ho1 io1
opian
l-.alpha.-narcotine
coscotabs
.alpha.-narcotine
nicolane
nsc-5366
vadebex
capval
o-methylnarcotoline
methoxyhydrastine
lyobex
tusscapine
narcosine
noscapin
1(3h)-isobenzofuranone,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl)-, [s-(r*,s*)]-
opianine
narcompren
longatin
hederix (free base)
narcotine
terbenol
phthalide,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl)-
noscapalin
key-tusscapine
coscopin
noscapal
nipaxon
opianin
nsc 5366
noscopine
NCI60_004322
(3s)-3-[(5r)-6-methyl-4-(methyloxy)-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-6,7-bis(methyloxy)-2-benzofuran-1(3h)-one
l-alpha-2-methyl-8-methoxy-6,7-methylenedioxy-1-(6,7-dimethoxy-3-phthalidyl)-1,2,3,4-tetrahydroisoquinaline
einecs 204-899-2
l-alpha-noscapine
longactin
noskapin
narcotine, (+-)-
(-)-3-(2-methyl-6,7-methylendioxy-8-methoxy-1-isochinolyl)-6,7-dimethoxyphthalid
noscapinum [inn-latin]
(-)-narcotine
5-(6,7-dimethoxyphthalidyl)-5,6,7,8-tetrahydro-4-methoxy-8-methyl-1,3-dioxolo(4,5-g)isoquinoline
1(3h)-isobenzofuranone, 6,7-dimethoxy-3-((5r)-5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-, (3s)-rel-
brn 0099933
1(3h)-isobenzofuranone, 6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-, (r*,s*)-
noscapina [inn-spanish]
hsdb 3372
8-methoxyhydrastin
coscopin (van)
nsc 96350
noscapine dl-form
(-)-alpha-norcotine
l-alpha-narcotine
1(3h)-isobenzofuranone, 6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-, (s-(r*,s*))-
PRESTWICK2_000563
PRESTWICK3_000563
PRESTWICK_959
cas-128-62-1
tocris-1697
NCGC00023230-02
NCGC00016388-01
(3s)-6,7-dimethoxy-3-[(5r)-4-methoxy-6-methyl-7,8-dihydro-5h-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3h-isobenzofuran-1-one
1(3h)-isobenzofuranone, 6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)-isoquinolin-5-yl), (s-(r*,s*))-
(-)-.alpha.-narcotine
BSPBIO_000346
BPBIO1_000382
CBMICRO_048259
BIM-0048054.P001
noscapine
alpha-narcotine
128-62-1
C09592
noscapine (jp17/usp/inn)
noscapine (tn)
D01036
LOPAC0_000840
(s,r)-noscapine, 97%
MLS000069475
smr000059119
SPBIO_002565
PRESTWICK0_000563
PRESTWICK1_000563
NCGC00023230-04
NCGC00023230-07
NCGC00023230-05
MLS001060855
STK054401
(3s)-6,7-dimethoxy-3-[(5r)-4-methoxy-6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-2-benzofuran-1(3h)-one
NCGC00023230-08
AKOS000278036
narcotinum
noscapinum
chebi:73237 ,
CHEMBL364713
(3s)-6,7-dimethoxy-3-[(5r)-5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl]-1(3h)-isobenzofuranone
HMS1569B08
HMS2096B08
(+/-)-noscapine
BBL012344
dtxsid4023385 ,
tox21_110413
dtxcid303385
CCG-204096
HMS2269P05
1(3h)-isobenzofuranone, 6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-, (r*,s*)-(+-)-
(+-)-alpha-narcotine
unii-a4c6we7bzn
(+-)-noscapine
a4c6we7bzn ,
(-)-noscapine
(-)-alpha-narcotine
1(3h)-isobenzofuranone, 6,7-dimethoxy-3-((5r)-5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-, (3s)-
noscapine [usp:inn:ban:jan]
4-27-00-06838 (beilstein handbook reference)
ccris 9304
noscapina
unii-8v32u4aoqu
8v32u4aoqu ,
bdbm50424716
noscapine [mart.]
noscapine [usp-rs]
noscapine [usp monograph]
noscapine [who-ip]
noscapine [inn]
noscapine [who-dd]
noscapine [ep monograph]
noscapine [mi]
noscapine [jan]
noscapine [hsdb]
noscapinum [who-ip latin]
narcotinum [hpus]
SCHEMBL4559
NCGC00023230-10
tox21_110413_1
noscapine dl-form [mi]
noscapine, (+/-)-
(+/-)-.alpha.-narcotine
CS-5115
W-201012
(s)-6,7-dimethoxy-3-((r)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)isobenzofuran-1(3h)-one
AC-33191
HY-13716
(3s)-6,7-dimethoxy-3-[(5r)-4-methoxy-6-methyl-2h,5h,6h,7h,8h-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-1,3-dihydro-2-benzofuran-1-one
mfcd00069316
noscapine, united states pharmacopeia (usp) reference standard
noscapine, european pharmacopoeia (ep) reference standard
noscapine 1.0 mg/ml in acetonitrile
(-)-a-narcotine
noscapine (jp15/usp/inn)
SR-01000075529-6
Q60998699
noscapine (narcotine)
VS-03291
DB06174
gtpl10212
SDCCGSBI-0048054.P004
NCGC00023230-14
EN300-24402818
08N ,
(3s)-6,7-dimethoxy-3-[(5r)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-2h-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-2-benzofuran-1(3h)-one
DTXSID901032089

Research Excerpts

Overview

Noscapine (NOSC) is an alkaloid derived from poppy opium with anticough, antistroke, anticancer, and antifibrotic properties. Nosca is an over-the-counter antitussive that has been used safely for decades.

ExcerptReferenceRelevance
"Noscapine is a phthalide isoquinoline alkaloid present in the latex of Papaver somniferum and has demonstrated potent antitumor activity in various cancer models. "( 9-Ethynyl noscapine induces G2/M arrest and apoptosis by disrupting tubulin polymerization in cervical cancer.
Kantevari, S; Kojja, V; Kommalapati, VK; Kumar, D; Nagireddy, PKR; Pedapati, RK; Tangutur, AD, 2022
)
2.57
"Noscapine is a phthalide isoquinoline alkaloid with antitussive activity. "( Immunomodifying and neuroprotective effects of noscapine: Implications for multiple sclerosis, neurodegenerative, and psychiatric disorders.
Altinoz, MA; Guloksuz, S; Ozpinar, A, 2022
)
2.42
"Noscapine (NSC) is a benzyl-isoquinoline alkaloid discovered in 1930 as an antitussive agent. "( Biomimetic photooxidation of noscapine sensitized by a riboflavin derivative in water: The combined role of natural dyes and solar light in environmental remediation.
Battiston, D; Calza, P; Fabbri, D; Marin, ML; Miranda, MA; Pavanello, A, 2022
)
2.46
"Noscapine is an isolated compound from the opium poppy, with distinctive chiral structure and chemistry, interacts with other compounds due to having multiple π-acceptors, hydrogen bond acceptors, and ionic sites. "( A new chiral stationary phase based on noscapine: Synthesis, enantioseparation, and docking study.
Bararjanian, M; Faraji-Shovey, A; Ghassempour, A; Mousavimanesh, Z; Sadr, AS; Salehi, P; Shahnani, M, 2022
)
2.43
"Noscapine is a proficient anticancer drug active against wide variety of tumors including lung cancer. "( Comparative assessment of 9-bromo noscapine ionic liquid and noscapine: Synthesis, in-vitro studies plus computational & biophysical evaluation with human hemoglobin.
Chandra, R; Kukreti, S; Mishra, N; Sehrawat, H; Sewariya, S; Singh, MB; Singh, P, 2023
)
2.63
"Noscapine is an over-the-counter antitussive that has been used safely for several decades."( Noscapine alleviates unilateral ureteral obstruction-induced inflammation and fibrosis by regulating the TGFβ1/Smads signaling pathways.
Chang, MY; Chen, KH; Hsu, HH; Hung, CC; Ko, YC; Yang, CW; Yang, HY, 2024
)
3.61
"Noscapine is an antitumor alkaloid derived from Papaver somniferum plants. "( Noscapine protects the H9c2 cardiomyocytes of rats against oxygen-glucose deprivation/reperfusion injury.
Barati, M; Golab, F; Jafari-Sabet, M; Moazam, A; Mohamadrezaei, H; Safari, S; Soltani, H; Vahabzadeh, G, 2020
)
3.44
"Noscapine is a natural alkaloid that is used as an antitussive medicine. "( Structural Basis of Noscapine Activation for Tubulin Binding.
Bargsten, K; Bennani, YL; Canales, Á; Díaz, JF; Jiménez-Barbero, J; Oliva, MA; Prota, AE; Rodríguez-Salarichs, J; Steinmetz, MO, 2020
)
2.32
"Noscapine (NOSC) is an alkaloid derived from poppy opium with anticough, antistroke, anticancer, and antifibrotic properties."( Noscapine Acts as a Protease Inhibitor of In Vitro Elastase-Induced Collagen Deposition in Equine Endometrium.
Amaral, A; Fernandes, C; Ferreira-Dias, G; Rebordão, MR; Skarzynski, DJ; Szóstek-Mioduchowska, A, 2021
)
2.79
"Noscapine is a natural product first isolated from the opium poppy (Papaver somniferum L.) with anticancer properties. "( Identification of novel anti-cancer agents by the synthesis and cellular screening of a noscapine-based library.
Bararjanian, M; Bischoff-Kont, I; Fürst, R; Hadian, N; Hassanpour, Z; Jung, Y; Lucena-Agell, D; Mohebbi, M; Nasiri, HR; Nejad-Ebrahimi, S; Nemati, F; Oliva, MA; Salehi, P; Schaerlaekens, S, 2021
)
2.29
"Noscapine is an antitumor alkaloid produced in opium poppy (Papaver somniferum) and some members of the Papaveraceae family. "( The effects of promoter variations of the N-Methylcanadine 1-Hydroxylase (CYP82Y1) gene on the noscapine production in opium poppy.
Abbasi, A; Abedini, D; Monfared, SR, 2018
)
2.14
"Noscapine is a non-narcotic, antitussive alkaloid isolated from plants of Papaveraceae family. "( Insights into the structure and tubulin-targeted anticancer potential of N-(3-bromobenzyl) noscapine.
Cheriyamundath, S; Kantevari, S; Lopus, M; Mahaddalkar, T; Reddy Nagireddy, PK; Sridhar, B, 2019
)
2.18
"Noscapine is a phthalide isoquinoline alkaloid that easily traverses the blood brain barrier and has been used for years as an antitussive agent with high safety. "( Noscapine, a Non-addictive Opioid and Microtubule-Inhibitor in Potential Treatment of Glioblastoma.
Altinoz, MA; Elmaci, İ; Hacimuftuoglu, A; Hacker, E; Ozpinar, A; Topcu, G, 2019
)
3.4
"Noscapine (NOS) is a non-narcotic opium alkaloid with anti-tumor activity. "( Synergistic suppression of noscapine and conventional chemotherapeutics on human glioblastoma cell growth.
Joshi, HC; Li, S; Liu, X; Qi, Q; Ye, K, 2013
)
2.13
"Noscapine is an antitussive and potential anticancer drug. "( Characterization of inhibition kinetics of (S)-warfarin hydroxylation by noscapine: implications in warfarin therapy.
Jeong, H; Kunze, KL; Seguin, RP; Zhang, N; Zhang, YY, 2013
)
2.06
"Noscapine is a phthalideisoquinoline alkaloid investigated for its potent pharmacological properties. "( CYP82Y1 is N-methylcanadine 1-hydroxylase, a key noscapine biosynthetic enzyme in opium poppy.
Dang, TT; Facchini, PJ, 2014
)
2.1
"Noscapine is a biologically active molecule with anticancer activity among other things. "( Fragmentation study of noscapine derivatives under electrospray conditions.
Kéki, S; Kuki, Á; Nagy, L; Sipos, A; Szabó, K; Zsuga, M, 2014
)
2.16
"Noscapine is a phthalideisoquinoline alkaloid, which represents a class of plant specialized metabolites within the large and structurally diverse group of benzylisoquinoline alkaloids. "( Noscapine comes of age.
Chen, X; Dang, TT; Facchini, PJ, 2015
)
3.3
"Noscapine is an opium-derived kinder-gentler microtubule-modulating drug, currently in Phase I/II clinical trials for cancer chemotherapy. "( Design, synthesis and biological evaluation of di-substituted noscapine analogs as potent and microtubule-targeted anticancer agents.
Aneja, R; Gundala, SR; Gupta, KK; Hamelberg, D; Karna, P; Lopus, M; Mishra, RC; Nagaraju, M; Panda, D; Reid, MD; Tandon, V, 2015
)
2.1
"Noscapine is an orally administrable drug used worldwide for cough suppression and has recently been demonstrated to disrupt microtubule dynamics and possess anticancer activity. "( CYLD Regulates Noscapine Activity in Acute Lymphoblastic Leukemia via a Microtubule-Dependent Mechanism.
Bao, G; Li, D; Liu, M; Luo, Y; Ran, J; Sun, L; Sun, X; Yan, B; Yang, Y; Zhang, L; Zhou, J, 2015
)
2.21
"Noscapine is a potential anticancer drug isolated from the opium poppy Papaver somniferum, and genes encoding enzymes responsible for the synthesis of noscapine have been recently discovered to be clustered on the genome of P. "( Engineering biosynthesis of the anticancer alkaloid noscapine in yeast.
Li, Y; Smolke, CD, 2016
)
2.13
"Noscapine is a benzylisoquinoline alkaloid derived from the opium poppy Papaver somniferum."( Noscapine targets EGFR
He, M; Jiang, L; Ren, Z; Wang, G; Wang, J, 2016
)
2.6
"Noscapine is an alkaloid present in the latex of Papaver somniferum. "( Induction of acetylation and bundling of cellular microtubules by 9-(4-vinylphenyl) noscapine elicits S-phase arrest in MDA-MB-231 cells.
Cheriyamundath, S; Kantevari, S; Lopus, M; Mahaddalkar, T, 2017
)
2.12
"Noscapine is a nontoxic ingredient in cough medicine currently used in clinical trials for patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia to assess antitumor efficacy."( Noscapine induces apoptosis in human glioma cells by an apoptosis-inducing factor-dependent pathway.
Lukyanov, Y; Newcomb, EW; Schnee, T; Smirnova, I; Zagzag, D, 2008
)
2.51
"Noscapine is an isoqiunoline alkaloid found in opium latex. "( The anti-cancer activity of noscapine: a review.
Mahmoudian, M; Rahimi-Moghaddam, P, 2009
)
2.09
"Noscapine (NOS) is a unique class of tubulin-binding anticancer agents. "( Inclusion complexes of noscapine in beta-cyclodextrin offer better solubility and improved pharmacokinetics.
Aneja, R; Bharatam, PV; Chandra, R; Dhiman, N; Katyal, A; Madan, J; Parmar, VK; Sardana, S, 2010
)
2.11
"Noscapine is a benzylisoquinoline alkaloid produced in opium poppy (Papaver somniferum) and other members of the Papaveraceae. "( Characterization of three O-methyltransferases involved in noscapine biosynthesis in opium poppy.
Dang, TT; Facchini, PJ, 2012
)
2.06
"Noscapine is an antitumor alkaloid from opium poppy that binds tubulin, arrests metaphase, and induces apoptosis in dividing human cells. "( A Papaver somniferum 10-gene cluster for synthesis of the anticancer alkaloid noscapine.
Bowser, TA; Gazda, V; Graham, IA; He, Z; Kaminski, F; Kern, M; Larson, TR; Li, Y; Meade, F; Teodor, R; Vaistij, FE; Walker, C; Winzer, T, 2012
)
2.05
"Noscapine is a promising anti-tumour agent. "( Metabolic map and bioactivation of the anti-tumour drug noscapine.
Cheng, J; Fang, ZZ; Gonzalez, FJ; Krausz, KW; Li, F; Tanaka, N, 2012
)
2.07
"Noscapine is a multifunctional molecule i.e."( A review on noscapine, and its impact on heme metabolism.
Chandra, A; Chandra, R; Dass, SK; Kumari, K; Singh, H; Singh, P, 2013
)
1.49
"Noscapine is a phthalideisoquinoline alkaloid isolated from the opium poppy Papaver somniferum. "( Synthesis and biological evaluation of N-substituted noscapine analogues.
Capuano, B; DeBono, AJ; Pouton, CW; Scammells, PJ; Ventura, S; Xie, JH, 2012
)
2.07
"Noscapine is an opioid antitussive, which acts anti cancer via blocking microtubule dynamics."( Noscapine and diltiazem augment taxol and radiation-induced S-phase arrest and clonogenic death of C6 glioma in vitro.
Altinoz, MA; Bilir, A; Del Maestro, RF; Gedikoglu, G; Ozcan, E; Tuna, S, 2006
)
2.5
"Noscapine hydrochloride is a centrally acting antitussive opium derivative widely used in cough suppressants. "( Noscapine hydrochloride disrupts the mitotic spindle in mammalian cells and induces aneuploidy as well as polyploidy in cultured human lymphocytes.
Eastmond, DA; Guzzie, P; Muehlbauer, P; Schuler, M, 1999
)
3.19

Effects

Noscapine has been mentioned as one of the effective drugs with potential therapeutic applications. It has several anti-inflammatory, anti-angiogenic, and anti-fibrotic effects. Its low solubility and large size results in its lower efficacy in the clinic.

ExcerptReferenceRelevance
"Noscapine has since been discovered to arrest cells at mitosis, albeit with moderately weak activity."( Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
Capuano, B; DeBono, A; Scammells, PJ, 2015
)
1.42
"Noscapine has been mentioned as one of the effective drugs with potential therapeutic applications. "( Biological and pharmacological activities of noscapine: Focusing on its receptors and mechanisms.
Askari, VR; Nourbakhsh, F, 2021
)
2.32
"Noscapine (NOS) has several anti-inflammatory, anti-angiogenic, and anti-fibrotic effects, but its low solubility and large size results in its lower efficacy in the clinic."( Preparation and characterization of solid lipid nanoparticles encapsulated noscapine and evaluation of its protective effects against imiquimod-induced psoriasis-like skin lesions.
Askari, VR; Baradaran Rahimi, V; Golmohammadzadeh, S; Jaafari, MR; Kamali, H; Rahmanian-Devin, P; Sanei-Far, Z, 2023
)
1.86
"Noscapine has low toxicity and recently it was also found to possess cytotoxic activity which led to the development of many noscapine analogues."( A new antiproliferative noscapine analogue: chemical synthesis and biological evaluation.
Abou El-Magd, RM; Churchill, CD; Ghaly, PE; Tuszynski, JA; West, FG, 2016
)
1.46
"Noscapine has demonstrated potent antitumour activity and minimum toxicity in cancer models. "( Prophylactic noscapine therapy inhibits human prostate cancer progression and metastasis in a mouse model.
Barken, I; Geller, J; Rogosnitzky, M, 2010
)
2.17
"Noscapine has recently been shown to potentiate the anti-cancer effects of several therapies by inducing apoptosis in various malignant cells without any detectable toxicity in cells or tissues."( Noscapine induces mitochondria-mediated apoptosis in human colon cancer cells in vivo and in vitro.
Dong, WG; Lei, XF; Liu, M; Peng, XL; Yang, ZR; Zhang, JX, 2012
)
2.54

Actions

Noscapine displays weak anticancer efficacy and numerous research efforts have attempted to generate more potent noscapine analogues. Noscapine plays an important role in the regulation of cell growth and death.

ExcerptReferenceRelevance
"Noscapine displays weak anticancer efficacy and numerous research efforts have attempted to generate more potent noscapine analogues. "( A Novel Class of N-Sulfonyl and N-Sulfamoyl Noscapine Derivatives that Promote Mitotic Arrest in Cancer Cells.
Callaghan, R; Capuano, B; Devine, SM; Gao, X; Scammells, PJ; Yan, A; Yong, C, 2019
)
2.22
"Noscapine plays an important role in the regulation of cell growth and death. "( Noscapine induces mitochondria-mediated apoptosis in gastric cancer cells in vitro and in vivo.
Dong, WG; Lei, XF; Liao, F; Liu, M; Luo, XJ, 2011
)
3.25

Treatment

Noscapine treatment increased levels of total and Ser(15)-phosphorylated p53 protein in SK-SY5Y cells. The treatment with noscapine upregulated Bax and Cytochrome c (Cyt-c) protein, downregulated Bcl-2 protein.

ExcerptReferenceRelevance
"Noscapine pretreatment and treatment also reduced tumour weight, the incidence of metastasis and primary tumour inhibition rate."( Prophylactic noscapine therapy inhibits human prostate cancer progression and metastasis in a mouse model.
Barken, I; Geller, J; Rogosnitzky, M, 2010
)
1.45
"The Noscapine treatment increased levels of total and Ser(15)-phosphorylated p53 protein in SK-SY5Y cells, but the proapoptotic response to this agent was maintained even after knockdown of the p53 protein level."( Noscapine induced apoptosis via downregulation of survivin in human neuroblastoma cells having wild type or null p53.
Cao, G; He, J; Joshi, HC; Li, S; Tang, S; Tong, Q, 2012
)
2.3
"The treatment with noscapine upregulated Bax and Cytochrome c (Cyt-c) protein, downregulated Bcl-2 protein."( Noscapine induces mitochondria-mediated apoptosis in gastric cancer cells in vitro and in vivo.
Dong, WG; Lei, XF; Liao, F; Liu, M; Luo, XJ, 2011
)
2.13

Toxicity

ExcerptReferenceRelevance
"Noscapine, a phthalideisoquinoline alkaloid derived from opium, has been used as an oral anti-tussive agent and has shown very few toxic effects in animals or humans."( Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses.
Archer, DR; Grossniklaus, HE; Joshi, HC; Kapp, JA; Ke, Y; Ye, K, 2000
)
3.19
" Secondary end-points were the rate of control of chronic cough at each step of therapy, the duration of treatment required, changes in cough symptom score, health-related quality of life and possible adverse effects."( Efficacy and safety of modified sequential three-step empirical therapy for chronic cough.
Li, X; Liang, S; Liu, B; Lü, H; Qiu, Z; Wang, L; Wang, Y; Wei, W; Yu, L, 2010
)
0.36

Pharmacokinetics

Noscapine hydrochloride showed faster absorption and gave a higher peak concentration than the embonate. Noscapine has an elimination half-life of 2.

ExcerptReferenceRelevance
" Noscapine hydrochloride showed faster absorption and gave a higher peak concentration than the embonate."( Comparative bioavailability and pharmacokinetics of noscapine hydrogen embonate and noscapine hydrochloride.
Haikala, V; Marvola, M; Sothmann, A, 1986
)
1.43
" Pharmacokinetic studies of noscapine were performed in mice following intravenous bolus at 10 mg/kg and oral administrations at 75, 150, and 300 mg/kg."( Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent.
Aneja, R; Arora, SK; Awasthi, A; Chandra, R; Dhiman, N; Idnani, J; Joshi, HC, 2007
)
0.88
" In vivo pharmacokinetic (PK), organ toxicity evaluation of combinations, microsomal stability and in vitro cytochrome P450 (CYP) inhibition effects of Nos, Cap and Pip using human liver microsomes were performed."( Noscapine recirculates enterohepatically and induces self-clearance.
Aneja, R; Gundala, SR; Jadhav, GR; Mukkavilli, R; Reid, MD; Vangala, S; Yang, C, 2015
)
1.86
" Furthermore, in vivo pharmacokinetic data showed the sustained release plasma concentration time curve with significant (p < 0."( Sustained release dosage form of noscapine HCl using hot melt extrusion (HME) technique: formulation and pharmacokinetics.
Bagde, A; Nottingham, E; Patel, K; Patel, N; Singh, M, 2021
)
0.9

Compound-Compound Interactions

ExcerptReferenceRelevance
"The aim of this study was to investigate the anticancer activity and mechanism of action of Noscapine alone and in combination with Doxorubicin against triple negative breast cancer (TNBC)."( Antitumor activity of Noscapine in combination with Doxorubicin in triple negative breast cancer.
Chougule, MB; Jackson, T; Patel, AR; Singh, M, 2011
)
0.9

Bioavailability

Noscapine hydrochloride hydrate has enhanced solubility and bioavailability. Aniline 6 is 250-fold more potent than noscapine in reducing cell proliferation in rapidly dividing cells.

ExcerptReferenceRelevance
"The bioavailability of noscapine base administered in lozenges in a dose of 100 mg to twelve healthy volunteers, in a study using an open balanced cross-over design, was compared with that of 100 mg of noscapine hydrochloride given perorally as a mixture."( Relative bioavailability in man of noscapine administered in lozenges and mixture.
Bonde, J; Bundgaard, H; Christrup, LL; Jacobsen, L; Jensen, LN, 1992
)
0.87
"The relative bioavailability in 20 healthy volunteers of 100 mg, 200 mg and 300 mg tablets of noscapine and 200 mg as a solution has been assessed in a four-way cross-over study, with repeated administration of the 200 mg dose to assess intraindividual variability."( Pharmacokinetics of oral noscapine.
Alm, AT; Dahlström, B; Eckernäs, SA; Johansson, M; Karlsson, MO, 1990
)
0.8
"The relative bioavailability and pharmacokinetics of two orally administered aqueous suspensions of noscapine hydrogen embonate were compared with those of noscapine hydrochloride solution."( Comparative bioavailability and pharmacokinetics of noscapine hydrogen embonate and noscapine hydrochloride.
Haikala, V; Marvola, M; Sothmann, A, 1986
)
0.74
" Aniline 6 is orally bioavailable and is 250-fold more potent than noscapine in reducing cell proliferation in rapidly dividing cells."( Identification of novel and improved antimitotic agents derived from noscapine.
Anderson, JT; Bennani, YL; Boozer, S; Brunden, KR; Crumrine, C; Danzig, J; Dent, T; Faga, L; Harrington, JJ; Hodnick, WF; Murphy, SM; Pawlowski, G; Perry, R; Raber, A; Rundlett, SE; Stricker-Krongrad, A; Ting, AE; Wang, J, 2005
)
0.8
" Since orally available anticancer drugs are rare, therefore, noscapine, an innocuous agent, having a mean oral bioavailability of 31."( Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent.
Aneja, R; Arora, SK; Awasthi, A; Chandra, R; Dhiman, N; Idnani, J; Joshi, HC, 2007
)
0.83
"87-fold increase in bioavailability of NOS upon complexation in the beta-CD inclusion complex state as compared to free NOS."( Inclusion complexes of noscapine in beta-cyclodextrin offer better solubility and improved pharmacokinetics.
Aneja, R; Bharatam, PV; Chandra, R; Dhiman, N; Katyal, A; Madan, J; Parmar, VK; Sardana, S, 2010
)
0.67
"Our studies propose for the first time a stable NOS-beta-CD inclusion complex as an effective approach to enhance the solubility and bioavailability of NOS for anticancer therapy."( Inclusion complexes of noscapine in beta-cyclodextrin offer better solubility and improved pharmacokinetics.
Aneja, R; Bharatam, PV; Chandra, R; Dhiman, N; Katyal, A; Madan, J; Parmar, VK; Sardana, S, 2010
)
0.67
" Nanoparticles made of human serum albumin (HSA) represent promising strategy for targeted drug delivery to tumor cells by enhancing the drug's bioavailability and distribution, and reducing the body's response towards drug resistance."( Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis.
Kulamarva, A; Malhotra, M; Mirzaei, M; Prakash, S; Sebak, S, 2010
)
0.61
" Despite its nontoxic attributes, significant elimination of the disease has not been achieved, perhaps since the bioavailability of noscapine to tumors saturates at an oral dose of 300 mg/kg body weight."( Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy.
Abdalla, MO; Aneja, R; Karna, P; Mao, H; Sajja, HK; Turner, T; Yates, C, 2011
)
0.99
" However, because of unpredictable parameters involved in poor solubility and the low oral bioavailability of these chemotherapeutics during the early phases of drug development, they often have an unusual pharmacokinetic profile."( Nanosolvated microtubule-modulating chemotherapeutics: a case-to-case study.
Chandra, R; Jain, B; Jain, UK; Jain, V; Katare, OP; Kumar, M; Madan, J; Pandey, RS; Saini, J; Tiwari, P, 2013
)
0.39
" Its pharmacokinetic limitations such as low bioavailability and high ED50 impede development of clinically relevant treatment regimens."( Sterically stabilized gelatin microassemblies of noscapine enhance cytotoxicity, apoptosis and drug delivery in lung cancer cells.
Aneja, R; Jain, UK; Katare, OP; Katyal, A; Madan, J; Pandey, RS, 2013
)
0.64
"The main objective of the present study was to develop formulations of noscapine hydrochloride hydrate with enhanced solubility and bioavailability using co-solvent- and cyclodextrin-based approaches."( Formulation approaches to improving the delivery of an antiviral drug with activity against seasonal flu.
Green, CE; Kelly, T; Mutyam, SK; O'Loughlin, K; Sammeta, SM; Shankar, GN; Wang, L; Werner, MH, 2015
)
0.65
" The effect of 1-5% w/v of CP on oral bioavailability of Nos (150 mg/kg) was evaluated in Sprague-Dawley rats."( Epithelial transport of noscapine across cell monolayer and influence of absorption enhancers on in vitro permeation and bioavailability: implications for intestinal absorption.
Chougule, MB; Jackson, T; Patel, AR; Patlolla, R; Singh, M, 2014
)
0.71
" Furthermore, in vivo pharmacokinetic evaluation of 6b, 8b and 8c revealed at least 1-2-fold improvement in their bioavailability compared to noscapine."( Novel third-generation water-soluble noscapine analogs as superior microtubule-interfering agents with enhanced antiproliferative activity.
Ahad, S; Aneja, R; Gundala, SR; Hamelberg, D; Henary, M; Mukkavilli, R; Nagaraju, M; Narayana, L; Owens, EA; Panda, D; Sharma, V; Tandon, V; Yadav, Y, 2014
)
0.88
" Pharmacokinetic analysis revealed that formulation P1 had a prolonged half-life and better bioavailability compared to drug solution."( Nanoparticles Based on Linear and Star-Shaped Poly(Ethylene Glycol)-Poly(ε-Caprolactone) Copolymers for the Delivery of Antitubulin Drug.
Bonacucina, G; Casettari, L; Cespi, M; El Shamy, AA; Illum, L; Palmieri, GF; Sammour, OA; Shalaby, KS; Soliman, ME, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Overall, HME can be used to enhance the bioavailability and achieve the pH-independent solubility of weakly basic drugs like Nos HCl."( Sustained release dosage form of noscapine HCl using hot melt extrusion (HME) technique: formulation and pharmacokinetics.
Bagde, A; Nottingham, E; Patel, K; Patel, N; Singh, M, 2021
)
0.9

Dosage Studied

Noscapine and ethanol antagonised the ethanol-induced elevation of cytochrome P-450 levels. Repeated administration of noscapine tablets and solution yielded higher AUC on the second dosing occasion.

ExcerptRelevanceReference
"Derivatization of the alkaloids cephaeline, codeine, emetine, ephedrine, morphine, narcotine and others with dansyl chloride has been studied with the aim of developing a sensitive and specific liquid chromatographic method for these substances in complex pharmaceutical dosage forms."( Liquid chromatography of dansyl derivatives of some alkaloids and the application to the analysis of pharmaceuticals.
Frei, RW; Santi, W; Thomas, M, 1976
)
0.26
" Chewing gum containing this compound showed, however, a low level of drug release both in vitro and in vivo and is therefore not a suitable dosage form."( Chewing gum and lozenges as delivery systems for noscapine.
Bundgaard, H; Christrup, LL; Jensen, LN; Menger, N, 1991
)
0.54
" Repeated administration of noscapine tablets and solution yielded higher AUC on the second dosing occasion."( Pharmacokinetics of oral noscapine.
Alm, AT; Dahlström, B; Eckernäs, SA; Johansson, M; Karlsson, MO, 1990
)
0.88
"A high-performance liquid chromatography procedure for the simultaneous determination of aminophylline, methoxyphenamine hydrochloride, noscapine and chlorphenamine maleate in commercially available compound capsule dosage forms has been developed and validated."( HPLC determination of aminophylline, methoxyphenamine hydrochloride, noscapine and chlorphenamine maleate in compound dosage forms with an aqueous-organic mobile phase.
Tang, C; Wu, X; Yin, C, 2003
)
0.76
" Our results indicate that the combination dosage of noscapine and ethanol antagonised the ethanol-induced elevation of cytochrome P-450 levels."( Modulatory influence of noscapine on the ethanol-altered hepatic biotransformation system enzymes, glutathione content and lipid peroxidation in vivo in rats.
Aneja, R; Chandra, R; Katyal, A,
)
0.69
" PCOS induced rats were administered varying dosing regimens of noscapine and were further compared with flutamide, the conventional drug for PCOS."( Relevance of an opioid, noscapine in reducing cystogeneses in rat experimental model of polycystic ovary syndrome.
Priyadarshani, A, 2009
)
0.9
" In this study, to provide a basis for warfarin dosage adjustment, the inhibition kinetics of noscapine against warfarin metabolism was characterized."( Characterization of inhibition kinetics of (S)-warfarin hydroxylation by noscapine: implications in warfarin therapy.
Jeong, H; Kunze, KL; Seguin, RP; Zhang, N; Zhang, YY, 2013
)
0.84
" Therefore, the purpose of this study was to achieve pH-independent drug release by developing the sustained release dosage form of Nos HCl using biodegradable polymer Eudragit RLPO and FDA-approved pH modifier citric acid (CA) by hot melt extrusion (HME) technique."( Sustained release dosage form of noscapine HCl using hot melt extrusion (HME) technique: formulation and pharmacokinetics.
Bagde, A; Nottingham, E; Patel, K; Patel, N; Singh, M, 2021
)
0.9
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antitussiveAn agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (7)

ClassDescription
benzylisoquinoline alkaloidAny isoquinoline alkaloid based on a benzylisoquinoline skeleton.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
cyclic acetalAn acetal in the molecule of which the acetal carbon and one or both oxygen atoms thereon are members of a ring.
isobenzofuranoneA 2-benzofuran containing one or more oxo groups.
organic heterobicyclic compound
organic heterotricyclic compoundAn organic tricyclic compound in which at least one of the rings of the tricyclic skeleton contains one or more heteroatoms.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
noscapine biosynthesis725
noscapine biosynthesis1123

Protein Targets (78)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency39.81070.044717.8581100.0000AID485294
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.39810.100020.879379.4328AID588453
Fumarate hydrataseHomo sapiens (human)Potency35.48130.00308.794948.0869AID1347053
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624146
TDP1 proteinHomo sapiens (human)Potency32.69870.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency29.30330.000714.592883.7951AID1259369; AID1259392
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency23.71010.001022.650876.6163AID1224839
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency0.43650.01237.983543.2770AID1645841
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency33.49150.001530.607315,848.9004AID1224849; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency29.84700.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency17.13520.005428.02631,258.9301AID1346982; AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency29.84930.000229.305416,493.5996AID1259244
GVesicular stomatitis virusPotency0.10960.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency4.89750.00108.379861.1304AID1645840
polyproteinZika virusPotency35.48130.00308.794948.0869AID1347053
ParkinHomo sapiens (human)Potency20.59620.819914.830644.6684AID720572
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency23.77810.035520.977089.1251AID504332
cytochrome P450 2C19 precursorHomo sapiens (human)Potency0.15850.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency0.12590.00636.904339.8107AID883
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID488953
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency10.32250.00419.984825.9290AID504444
mitogen-activated protein kinase 1Homo sapiens (human)Potency31.62280.039816.784239.8107AID995
atrial natriuretic peptide receptor 2 precursorHomo sapiens (human)Potency16.48160.00669.809418.4927AID1347050
ras-related protein Rab-9AHomo sapiens (human)Potency115.82100.00022.621531.4954AID485297
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency14.12540.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency14.12540.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency14.12540.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency26.10110.004611.374133.4983AID624297
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency1.99530.031610.279239.8107AID884; AID885
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)Potency22.38720.058010.694926.6086AID602310
lethal factor (plasmid)Bacillus anthracis str. A2012Potency12.58930.020010.786931.6228AID912
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency29.84930.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency0.10960.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency0.10960.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency26.60320.002319.595674.0614AID651631
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency29.84930.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency0.12590.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency0.10960.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency0.10960.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 2Homo sapiens (human)IC50 (µMol)2.60000.40003.10009.7000AID721751
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)8.17730.00002.800510.0000AID625248
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)0.40030.00002.398310.0000AID625247
Tubulin beta-2B chainBos taurus (cattle)IC50 (µMol)285.00000.25001.88388.7000AID1185191; AID1185192
Similar to alpha-tubulin isoform 1 Bos taurus (cattle)IC50 (µMol)285.00000.25001.87798.7000AID1185191; AID1185192
Similar to alpha-tubulin isoform 1 Bos taurus (cattle)IC50 (µMol)285.00000.25001.86568.7000AID1185191; AID1185192
Multidrug and toxin extrusion protein 1Homo sapiens (human)IC50 (µMol)34.50000.01002.765610.0000AID721754
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tubulin beta 8BHomo sapiens (human)Kd0.57900.57900.57900.5790AID1675128
Tubulin beta-4A chainHomo sapiens (human)EC50 (µMol)50.00000.00900.36851.2300AID282705
Tubulin beta-4A chainHomo sapiens (human)Kd48.81300.05800.64431.8600AID1236526; AID1675128
Tubulin beta chainHomo sapiens (human)EC50 (µMol)50.00000.00900.36851.2300AID282705
Tubulin beta chainHomo sapiens (human)Kd48.81300.05800.64431.8600AID1236526; AID1675128
Tubulin alpha-3C chainHomo sapiens (human)EC50 (µMol)50.00000.00900.36851.2300AID282705
Tubulin alpha-3C chainHomo sapiens (human)Kd72.93000.05800.65741.8600AID1236526
Tubulin alpha-1B chainHomo sapiens (human)EC50 (µMol)50.00000.00900.36851.2300AID282705
Tubulin alpha-1B chainHomo sapiens (human)Kd72.93000.05800.65741.8600AID1236526
Tubulin alpha-4A chainHomo sapiens (human)EC50 (µMol)50.00000.00900.36851.2300AID282705
Tubulin alpha-4A chainHomo sapiens (human)Kd72.93000.05800.65741.8600AID1236526
Tubulin beta-4B chainHomo sapiens (human)EC50 (µMol)50.00000.00900.36851.2300AID282705
Tubulin beta-4B chainHomo sapiens (human)Kd48.81300.05800.64431.8600AID1236526; AID1675128
Tubulin beta-3 chainHomo sapiens (human)EC50 (µMol)50.00000.00900.36851.2300AID282705
Tubulin beta-3 chainHomo sapiens (human)Kd48.81300.05800.64431.8600AID1236526; AID1675128
Tubulin beta-2A chainHomo sapiens (human)EC50 (µMol)50.00000.00900.36851.2300AID282705
Tubulin beta-2A chainHomo sapiens (human)Kd48.81300.05800.64431.8600AID1236526; AID1675128
Tubulin beta-8 chainHomo sapiens (human)EC50 (µMol)50.00000.00900.36851.2300AID282705
Tubulin beta-8 chainHomo sapiens (human)Kd48.81300.05800.64431.8600AID1236526; AID1675128
Tubulin alpha-3E chainHomo sapiens (human)EC50 (µMol)50.00000.00900.36851.2300AID282705
Tubulin alpha-3E chainHomo sapiens (human)Kd72.93000.05800.65741.8600AID1236526
Tubulin alpha-1A chainHomo sapiens (human)EC50 (µMol)50.00000.00900.36851.2300AID282705
Tubulin alpha-1A chainHomo sapiens (human)Kd72.93000.05800.65741.8600AID1236526
Tubulin alpha-1C chainHomo sapiens (human)EC50 (µMol)50.00000.00900.36851.2300AID282705
Tubulin alpha-1C chainHomo sapiens (human)Kd72.93000.05800.65741.8600AID1236526
Tubulin beta-6 chainHomo sapiens (human)EC50 (µMol)50.00000.00900.36851.2300AID282705
Tubulin beta-6 chainHomo sapiens (human)Kd48.81300.05800.64431.8600AID1236526; AID1675128
Tubulin beta-2B chainHomo sapiens (human)EC50 (µMol)50.00000.00900.36851.2300AID282705
Tubulin beta-2B chainHomo sapiens (human)Kd48.81300.05800.64431.8600AID1236526; AID1675128
Tubulin beta-1 chainHomo sapiens (human)EC50 (µMol)50.00000.00900.36851.2300AID282705
Tubulin beta-1 chainHomo sapiens (human)Kd48.81300.05800.58941.8600AID1236526; AID1675128
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (271)

Processvia Protein(s)Taxonomy
mitotic cell cycleTubulin beta 8BHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta 8BHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processSolute carrier family 22 member 2Homo sapiens (human)
positive regulation of gene expressionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
monoatomic cation transportSolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin transportSolute carrier family 22 member 2Homo sapiens (human)
body fluid secretionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 2Homo sapiens (human)
amine transportSolute carrier family 22 member 2Homo sapiens (human)
putrescine transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transportSolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 2Homo sapiens (human)
choline transportSolute carrier family 22 member 2Homo sapiens (human)
dopamine transportSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 2Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
histamine transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 2Homo sapiens (human)
histamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
amino acid import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
L-arginine import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
export across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
L-alpha-amino acid transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of microtubule polymerizationTubulin beta-4A chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-4A chainHomo sapiens (human)
mitotic cell cycleTubulin beta-4A chainHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
odontoblast differentiationTubulin beta chainHomo sapiens (human)
microtubule-based processTubulin beta chainHomo sapiens (human)
cytoskeleton-dependent intracellular transportTubulin beta chainHomo sapiens (human)
natural killer cell mediated cytotoxicityTubulin beta chainHomo sapiens (human)
regulation of synapse organizationTubulin beta chainHomo sapiens (human)
spindle assemblyTubulin beta chainHomo sapiens (human)
cell divisionTubulin beta chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta chainHomo sapiens (human)
mitotic cell cycleTubulin beta chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-3C chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-3C chainHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-1B chainHomo sapiens (human)
microtubule-based processTubulin alpha-1B chainHomo sapiens (human)
cytoskeleton-dependent intracellular transportTubulin alpha-1B chainHomo sapiens (human)
cell divisionTubulin alpha-1B chainHomo sapiens (human)
cellular response to interleukin-4Tubulin alpha-1B chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-1B chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-4A chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-4A chainHomo sapiens (human)
natural killer cell mediated cytotoxicityTubulin beta-4B chainHomo sapiens (human)
mitotic cell cycleTubulin beta-4B chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-4B chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-3 chainHomo sapiens (human)
axon guidanceTubulin beta-3 chainHomo sapiens (human)
netrin-activated signaling pathwayTubulin beta-3 chainHomo sapiens (human)
dorsal root ganglion developmentTubulin beta-3 chainHomo sapiens (human)
mitotic cell cycleTubulin beta-3 chainHomo sapiens (human)
cerebral cortex developmentTubulin beta-2A chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-2A chainHomo sapiens (human)
mitotic cell cycleTubulin beta-2A chainHomo sapiens (human)
oocyte maturationTubulin beta-8 chainHomo sapiens (human)
spindle assembly involved in female meiosisTubulin beta-8 chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-8 chainHomo sapiens (human)
mitotic cell cycleTubulin beta-8 chainHomo sapiens (human)
microtubule-based processTubulin beta-2B chainBos taurus (cattle)
nervous system developmentTubulin beta-2B chainBos taurus (cattle)
positive regulation of axon guidanceTubulin beta-2B chainBos taurus (cattle)
biological_processTubulin alpha-3E chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-3E chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-3E chainHomo sapiens (human)
neuron migrationTubulin alpha-1A chainHomo sapiens (human)
startle responseTubulin alpha-1A chainHomo sapiens (human)
intracellular protein transportTubulin alpha-1A chainHomo sapiens (human)
microtubule-based processTubulin alpha-1A chainHomo sapiens (human)
centrosome cycleTubulin alpha-1A chainHomo sapiens (human)
smoothened signaling pathwayTubulin alpha-1A chainHomo sapiens (human)
memoryTubulin alpha-1A chainHomo sapiens (human)
adult locomotory behaviorTubulin alpha-1A chainHomo sapiens (human)
visual learningTubulin alpha-1A chainHomo sapiens (human)
response to mechanical stimulusTubulin alpha-1A chainHomo sapiens (human)
glial cell differentiationTubulin alpha-1A chainHomo sapiens (human)
gene expressionTubulin alpha-1A chainHomo sapiens (human)
dentate gyrus developmentTubulin alpha-1A chainHomo sapiens (human)
cerebellar cortex morphogenesisTubulin alpha-1A chainHomo sapiens (human)
pyramidal neuron differentiationTubulin alpha-1A chainHomo sapiens (human)
cerebral cortex developmentTubulin alpha-1A chainHomo sapiens (human)
cytoskeleton-dependent intracellular transportTubulin alpha-1A chainHomo sapiens (human)
response to tumor necrosis factorTubulin alpha-1A chainHomo sapiens (human)
locomotory exploration behaviorTubulin alpha-1A chainHomo sapiens (human)
microtubule polymerizationTubulin alpha-1A chainHomo sapiens (human)
forebrain morphogenesisTubulin alpha-1A chainHomo sapiens (human)
homeostasis of number of cells within a tissueTubulin alpha-1A chainHomo sapiens (human)
regulation of synapse organizationTubulin alpha-1A chainHomo sapiens (human)
synapse organizationTubulin alpha-1A chainHomo sapiens (human)
cell divisionTubulin alpha-1A chainHomo sapiens (human)
neuron apoptotic processTubulin alpha-1A chainHomo sapiens (human)
motor behaviorTubulin alpha-1A chainHomo sapiens (human)
cellular response to calcium ionTubulin alpha-1A chainHomo sapiens (human)
organelle transport along microtubuleTubulin alpha-1A chainHomo sapiens (human)
neuron projection arborizationTubulin alpha-1A chainHomo sapiens (human)
response to L-glutamateTubulin alpha-1A chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-1A chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-1A chainHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
organic cation transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
putrescine transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
thiamine transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
amino acid import across plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine import across plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-alpha-amino acid transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
proton transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
microtubule-based processTubulin alpha-1C chainHomo sapiens (human)
cytoskeleton-dependent intracellular transportTubulin alpha-1C chainHomo sapiens (human)
cell divisionTubulin alpha-1C chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-1C chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-1C chainHomo sapiens (human)
mitotic cell cycleTubulin beta-6 chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-6 chainHomo sapiens (human)
neuron migrationTubulin beta-2B chainHomo sapiens (human)
microtubule-based processTubulin beta-2B chainHomo sapiens (human)
cerebral cortex developmentTubulin beta-2B chainHomo sapiens (human)
modulation of chemical synaptic transmissionTubulin beta-2B chainHomo sapiens (human)
positive regulation of axon guidanceTubulin beta-2B chainHomo sapiens (human)
embryonic brain developmentTubulin beta-2B chainHomo sapiens (human)
mitotic cell cycleTubulin beta-2B chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-2B chainHomo sapiens (human)
platelet formationTubulin beta-1 chainHomo sapiens (human)
thyroid gland developmentTubulin beta-1 chainHomo sapiens (human)
microtubule polymerizationTubulin beta-1 chainHomo sapiens (human)
spindle assemblyTubulin beta-1 chainHomo sapiens (human)
thyroid hormone transportTubulin beta-1 chainHomo sapiens (human)
platelet aggregationTubulin beta-1 chainHomo sapiens (human)
mitotic cell cycleTubulin beta-1 chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-1 chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (104)

Processvia Protein(s)Taxonomy
GTPase activityTubulin beta 8BHomo sapiens (human)
metal ion bindingTubulin beta 8BHomo sapiens (human)
GTP bindingTubulin beta 8BHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta 8BHomo sapiens (human)
amine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-amino acid transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
choline transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
efflux transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
GTPase activityTubulin beta-4A chainHomo sapiens (human)
calcium ion bindingTubulin beta-4A chainHomo sapiens (human)
protein bindingTubulin beta-4A chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-4A chainHomo sapiens (human)
GTP bindingTubulin beta-4A chainHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
GTPase activityTubulin beta chainHomo sapiens (human)
structural molecule activityTubulin beta chainHomo sapiens (human)
protein bindingTubulin beta chainHomo sapiens (human)
protein domain specific bindingTubulin beta chainHomo sapiens (human)
ubiquitin protein ligase bindingTubulin beta chainHomo sapiens (human)
GTPase activating protein bindingTubulin beta chainHomo sapiens (human)
MHC class I protein bindingTubulin beta chainHomo sapiens (human)
protein-containing complex bindingTubulin beta chainHomo sapiens (human)
metal ion bindingTubulin beta chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta chainHomo sapiens (human)
GTP bindingTubulin beta chainHomo sapiens (human)
hydrolase activityTubulin alpha-3C chainHomo sapiens (human)
metal ion bindingTubulin alpha-3C chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-3C chainHomo sapiens (human)
GTP bindingTubulin alpha-3C chainHomo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
double-stranded RNA bindingTubulin alpha-1B chainHomo sapiens (human)
GTPase activityTubulin alpha-1B chainHomo sapiens (human)
structural molecule activityTubulin alpha-1B chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-1B chainHomo sapiens (human)
protein bindingTubulin alpha-1B chainHomo sapiens (human)
GTP bindingTubulin alpha-1B chainHomo sapiens (human)
ubiquitin protein ligase bindingTubulin alpha-1B chainHomo sapiens (human)
protein bindingTubulin alpha-4A chainHomo sapiens (human)
hydrolase activityTubulin alpha-4A chainHomo sapiens (human)
protein kinase bindingTubulin alpha-4A chainHomo sapiens (human)
metal ion bindingTubulin alpha-4A chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-4A chainHomo sapiens (human)
GTP bindingTubulin alpha-4A chainHomo sapiens (human)
double-stranded RNA bindingTubulin beta-4B chainHomo sapiens (human)
GTPase activityTubulin beta-4B chainHomo sapiens (human)
protein bindingTubulin beta-4B chainHomo sapiens (human)
MHC class I protein bindingTubulin beta-4B chainHomo sapiens (human)
metal ion bindingTubulin beta-4B chainHomo sapiens (human)
unfolded protein bindingTubulin beta-4B chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-4B chainHomo sapiens (human)
GTP bindingTubulin beta-4B chainHomo sapiens (human)
GTPase activityTubulin beta-3 chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-3 chainHomo sapiens (human)
protein bindingTubulin beta-3 chainHomo sapiens (human)
GTP bindingTubulin beta-3 chainHomo sapiens (human)
peptide bindingTubulin beta-3 chainHomo sapiens (human)
metal ion bindingTubulin beta-3 chainHomo sapiens (human)
netrin receptor bindingTubulin beta-3 chainHomo sapiens (human)
GTPase activityTubulin beta-2A chainHomo sapiens (human)
protein bindingTubulin beta-2A chainHomo sapiens (human)
metal ion bindingTubulin beta-2A chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-2A chainHomo sapiens (human)
GTP bindingTubulin beta-2A chainHomo sapiens (human)
molecular_functionTubulin beta-8 chainHomo sapiens (human)
GTPase activityTubulin beta-8 chainHomo sapiens (human)
metal ion bindingTubulin beta-8 chainHomo sapiens (human)
GTP bindingTubulin beta-8 chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-8 chainHomo sapiens (human)
GTPase activityTubulin beta-2B chainBos taurus (cattle)
metal ion bindingTubulin beta-2B chainBos taurus (cattle)
protein heterodimerization activityTubulin beta-2B chainBos taurus (cattle)
molecular_functionTubulin alpha-3E chainHomo sapiens (human)
protein bindingTubulin alpha-3E chainHomo sapiens (human)
hydrolase activityTubulin alpha-3E chainHomo sapiens (human)
metal ion bindingTubulin alpha-3E chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-3E chainHomo sapiens (human)
GTP bindingTubulin alpha-3E chainHomo sapiens (human)
structural molecule activityTubulin alpha-1A chainHomo sapiens (human)
protein bindingTubulin alpha-1A chainHomo sapiens (human)
hydrolase activityTubulin alpha-1A chainHomo sapiens (human)
identical protein bindingTubulin alpha-1A chainHomo sapiens (human)
protein-containing complex bindingTubulin alpha-1A chainHomo sapiens (human)
metal ion bindingTubulin alpha-1A chainHomo sapiens (human)
protein heterodimerization activityTubulin alpha-1A chainHomo sapiens (human)
GTP bindingTubulin alpha-1A chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-1A chainHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingMultidrug and toxin extrusion protein 1Homo sapiens (human)
organic cation transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-amino acid transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
thiamine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
antiporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
putrescine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
polyspecific organic cation:proton antiporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
structural molecule activityTubulin alpha-1C chainHomo sapiens (human)
protein bindingTubulin alpha-1C chainHomo sapiens (human)
hydrolase activityTubulin alpha-1C chainHomo sapiens (human)
metal ion bindingTubulin alpha-1C chainHomo sapiens (human)
GTP bindingTubulin alpha-1C chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-1C chainHomo sapiens (human)
molecular_functionTubulin beta-6 chainHomo sapiens (human)
GTPase activityTubulin beta-6 chainHomo sapiens (human)
protein bindingTubulin beta-6 chainHomo sapiens (human)
metal ion bindingTubulin beta-6 chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-6 chainHomo sapiens (human)
GTP bindingTubulin beta-6 chainHomo sapiens (human)
GTPase activityTubulin beta-2B chainHomo sapiens (human)
protein bindingTubulin beta-2B chainHomo sapiens (human)
metal ion bindingTubulin beta-2B chainHomo sapiens (human)
protein heterodimerization activityTubulin beta-2B chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-2B chainHomo sapiens (human)
GTP bindingTubulin beta-2B chainHomo sapiens (human)
GTPase activityTubulin beta-1 chainHomo sapiens (human)
metal ion bindingTubulin beta-1 chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-1 chainHomo sapiens (human)
GTP bindingTubulin beta-1 chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (71)

Processvia Protein(s)Taxonomy
microtubule cytoskeletonTubulin beta 8BHomo sapiens (human)
intercellular bridgeTubulin beta 8BHomo sapiens (human)
extracellular exosomeTubulin beta 8BHomo sapiens (human)
mitotic spindleTubulin beta 8BHomo sapiens (human)
microtubuleTubulin beta 8BHomo sapiens (human)
cytoplasmTubulin beta 8BHomo sapiens (human)
plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
membraneSolute carrier family 22 member 2Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 2Homo sapiens (human)
presynapseSolute carrier family 22 member 2Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nucleusTubulin beta-4A chainHomo sapiens (human)
cytosolTubulin beta-4A chainHomo sapiens (human)
microtubuleTubulin beta-4A chainHomo sapiens (human)
axonemeTubulin beta-4A chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-4A chainHomo sapiens (human)
internode region of axonTubulin beta-4A chainHomo sapiens (human)
neuronal cell bodyTubulin beta-4A chainHomo sapiens (human)
myelin sheathTubulin beta-4A chainHomo sapiens (human)
intercellular bridgeTubulin beta-4A chainHomo sapiens (human)
extracellular exosomeTubulin beta-4A chainHomo sapiens (human)
mitotic spindleTubulin beta-4A chainHomo sapiens (human)
microtubuleTubulin beta-4A chainHomo sapiens (human)
cytoplasmTubulin beta-4A chainHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
extracellular regionTubulin beta chainHomo sapiens (human)
nucleusTubulin beta chainHomo sapiens (human)
nuclear envelope lumenTubulin beta chainHomo sapiens (human)
cytoplasmTubulin beta chainHomo sapiens (human)
cytosolTubulin beta chainHomo sapiens (human)
cytoskeletonTubulin beta chainHomo sapiens (human)
microtubuleTubulin beta chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta chainHomo sapiens (human)
azurophil granule lumenTubulin beta chainHomo sapiens (human)
cytoplasmic ribonucleoprotein granuleTubulin beta chainHomo sapiens (human)
cell bodyTubulin beta chainHomo sapiens (human)
membrane raftTubulin beta chainHomo sapiens (human)
intercellular bridgeTubulin beta chainHomo sapiens (human)
extracellular exosomeTubulin beta chainHomo sapiens (human)
mitotic spindleTubulin beta chainHomo sapiens (human)
protein-containing complexTubulin beta chainHomo sapiens (human)
cytoplasmTubulin beta chainHomo sapiens (human)
microtubuleTubulin beta chainHomo sapiens (human)
nucleusTubulin alpha-3C chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-3C chainHomo sapiens (human)
microtubuleTubulin alpha-3C chainHomo sapiens (human)
cytoplasmTubulin alpha-3C chainHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
microtubule cytoskeletonTubulin alpha-1B chainHomo sapiens (human)
microtubuleTubulin alpha-1B chainHomo sapiens (human)
cytoplasmic microtubuleTubulin alpha-1B chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-1B chainHomo sapiens (human)
microtubuleTubulin alpha-1B chainHomo sapiens (human)
cytoplasmTubulin alpha-1B chainHomo sapiens (human)
extracellular regionTubulin alpha-4A chainHomo sapiens (human)
cytosolTubulin alpha-4A chainHomo sapiens (human)
cytoskeletonTubulin alpha-4A chainHomo sapiens (human)
microtubuleTubulin alpha-4A chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-4A chainHomo sapiens (human)
extracellular exosomeTubulin alpha-4A chainHomo sapiens (human)
cytoplasmTubulin alpha-4A chainHomo sapiens (human)
microtubuleTubulin alpha-4A chainHomo sapiens (human)
extracellular regionTubulin beta-4B chainHomo sapiens (human)
nucleusTubulin beta-4B chainHomo sapiens (human)
cytosolTubulin beta-4B chainHomo sapiens (human)
cytoskeletonTubulin beta-4B chainHomo sapiens (human)
microtubuleTubulin beta-4B chainHomo sapiens (human)
axonemal microtubuleTubulin beta-4B chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-4B chainHomo sapiens (human)
azurophil granule lumenTubulin beta-4B chainHomo sapiens (human)
intercellular bridgeTubulin beta-4B chainHomo sapiens (human)
extracellular exosomeTubulin beta-4B chainHomo sapiens (human)
mitotic spindleTubulin beta-4B chainHomo sapiens (human)
extracellular vesicleTubulin beta-4B chainHomo sapiens (human)
microtubuleTubulin beta-4B chainHomo sapiens (human)
cytoplasmTubulin beta-4B chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-3 chainHomo sapiens (human)
nucleusTubulin beta-3 chainHomo sapiens (human)
microtubuleTubulin beta-3 chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-3 chainHomo sapiens (human)
lamellipodiumTubulin beta-3 chainHomo sapiens (human)
filopodiumTubulin beta-3 chainHomo sapiens (human)
axonTubulin beta-3 chainHomo sapiens (human)
dendriteTubulin beta-3 chainHomo sapiens (human)
growth coneTubulin beta-3 chainHomo sapiens (human)
neuronal cell bodyTubulin beta-3 chainHomo sapiens (human)
intercellular bridgeTubulin beta-3 chainHomo sapiens (human)
extracellular exosomeTubulin beta-3 chainHomo sapiens (human)
cell peripheryTubulin beta-3 chainHomo sapiens (human)
mitotic spindleTubulin beta-3 chainHomo sapiens (human)
microtubuleTubulin beta-3 chainHomo sapiens (human)
cytoplasmTubulin beta-3 chainHomo sapiens (human)
nucleusTubulin beta-2A chainHomo sapiens (human)
microtubuleTubulin beta-2A chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-2A chainHomo sapiens (human)
intercellular bridgeTubulin beta-2A chainHomo sapiens (human)
extracellular exosomeTubulin beta-2A chainHomo sapiens (human)
mitotic spindleTubulin beta-2A chainHomo sapiens (human)
extracellular vesicleTubulin beta-2A chainHomo sapiens (human)
cytoplasmTubulin beta-2A chainHomo sapiens (human)
microtubuleTubulin beta-2A chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-8 chainHomo sapiens (human)
intercellular bridgeTubulin beta-8 chainHomo sapiens (human)
extracellular exosomeTubulin beta-8 chainHomo sapiens (human)
mitotic spindleTubulin beta-8 chainHomo sapiens (human)
meiotic spindleTubulin beta-8 chainHomo sapiens (human)
microtubuleTubulin beta-8 chainHomo sapiens (human)
cytoplasmTubulin beta-8 chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-2B chainBos taurus (cattle)
nucleusTubulin alpha-3E chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-3E chainHomo sapiens (human)
microtubuleTubulin alpha-3E chainHomo sapiens (human)
cytoplasmTubulin alpha-3E chainHomo sapiens (human)
condensed chromosomeTubulin alpha-1A chainHomo sapiens (human)
nucleusTubulin alpha-1A chainHomo sapiens (human)
cytosolTubulin alpha-1A chainHomo sapiens (human)
microtubuleTubulin alpha-1A chainHomo sapiens (human)
axonemal microtubuleTubulin alpha-1A chainHomo sapiens (human)
plasma membraneTubulin alpha-1A chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-1A chainHomo sapiens (human)
neuromuscular junctionTubulin alpha-1A chainHomo sapiens (human)
cytoplasmic ribonucleoprotein granuleTubulin alpha-1A chainHomo sapiens (human)
recycling endosomeTubulin alpha-1A chainHomo sapiens (human)
extracellular exosomeTubulin alpha-1A chainHomo sapiens (human)
microtubuleTubulin alpha-1A chainHomo sapiens (human)
cytoplasmTubulin alpha-1A chainHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
basolateral plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
apical plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
nucleusTubulin alpha-1C chainHomo sapiens (human)
microtubuleTubulin alpha-1C chainHomo sapiens (human)
cytoplasmic microtubuleTubulin alpha-1C chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-1C chainHomo sapiens (human)
vesicleTubulin alpha-1C chainHomo sapiens (human)
membrane raftTubulin alpha-1C chainHomo sapiens (human)
microtubuleTubulin alpha-1C chainHomo sapiens (human)
cytoplasmTubulin alpha-1C chainHomo sapiens (human)
nucleusTubulin beta-6 chainHomo sapiens (human)
microtubuleTubulin beta-6 chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-6 chainHomo sapiens (human)
intercellular bridgeTubulin beta-6 chainHomo sapiens (human)
extracellular exosomeTubulin beta-6 chainHomo sapiens (human)
mitotic spindleTubulin beta-6 chainHomo sapiens (human)
cytoplasmTubulin beta-6 chainHomo sapiens (human)
microtubuleTubulin beta-6 chainHomo sapiens (human)
nucleusTubulin beta-2B chainHomo sapiens (human)
microtubuleTubulin beta-2B chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-2B chainHomo sapiens (human)
intercellular bridgeTubulin beta-2B chainHomo sapiens (human)
mitotic spindleTubulin beta-2B chainHomo sapiens (human)
Schaffer collateral - CA1 synapseTubulin beta-2B chainHomo sapiens (human)
microtubuleTubulin beta-2B chainHomo sapiens (human)
cytoplasmTubulin beta-2B chainHomo sapiens (human)
cytoplasmTubulin beta-1 chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-1 chainHomo sapiens (human)
intercellular bridgeTubulin beta-1 chainHomo sapiens (human)
extracellular exosomeTubulin beta-1 chainHomo sapiens (human)
mitotic spindleTubulin beta-1 chainHomo sapiens (human)
microtubuleTubulin beta-1 chainHomo sapiens (human)
cytoplasmTubulin beta-1 chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (177)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID662234Antiproliferative activity against human SNU475 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1675128Binding affinity to CM5 chip immobilized beta tubulin (unknown origin) assessed as thermodynamic constants by SPR assay2020Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
Discovery of noscapine derivatives as potential β-tubulin inhibitors.
AID282716Bioavailability in mouse at 20 mg/kg, po2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Identification of novel and improved antimitotic agents derived from noscapine.
AID1236549Antitumor activity against human H460 cells xenografted in athymic nu/nu mouse assessed as tumor regression at 450 mg/kg/day, po administered for 24 days2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID662206Binding affinity to calf brain tubulin assessed as increase in fluorescence at 10 uM by fluorometry relative to control2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID662221Antiproliferative activity against human Bel7402 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1386567Cell cycle arrest in human PANC1 cells assessed as increase in accumulation at G2/M phase at 10 uM after 18 hrs by Hoechst 33342 staining based FACS analysis relative to control
AID1236524Cell cycle arrest in human HeLa cells assessed as accumulation at G2/M phase after 24 hrs by FACS analysis (Rvb = 16.5%)2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID1236528Inhibition of tubulin polymerization in human HeLa cells assessed as shortening of microtubules at 20 uM2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID1236567Cytotoxicity against human CEM cells2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID1236535Antiproliferative activity against human LN229 cells assessed as decrease in colony formation2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID1386565Cell cycle arrest in human MCF7 cells assessed as increase in accumulation at G2/M phase at 10 uM after 18 hrs by Hoechst 33342 staining based FACS analysis relative to control
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID1236538Cell cycle arrest in human U251 cells assessed as accumulation at G1 phase at 30 uM after 24 hrs by flow cytomtery analysis (Rvb = 59.62%)2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID1386572Cell cycle arrest in human PANC1 cells assessed as accumulation at S phase at 10 uM after 18 hrs by Hoechst 33342 staining based FACS analysis (Rvb = 11.1%)
AID282692Cell cycle arrest in HEK293EBNA cells by accumulation at G2/M phase cell at 50 uM relative to DMSO2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Identification of novel and improved antimitotic agents derived from noscapine.
AID1386580Absolute oral bioavailability in human at 150 mg
AID662226Antiproliferative activity against human JHH4 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1173391Antiproliferative activity against human A549 cells after 72 hrs by MTS assay2014Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24
Synthesis and biological evaluation of novel biaryl type α-noscapine congeners.
AID641763Inhibition of NF-kappaB activation in human TNFalpha-stimulated A549 cells preincubated for 2 hrs before TNFalpha challenge measured after 7 hrs post stimulation by luciferase reporter gene assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Synthesis and evaluation of macrocyclic diarylether heptanoid natural products and their analogs.
AID1236548Antitumor activity against human H460 cells xenografted in athymic nu/nu mouse assessed as tumor regression at 300 mg/kg/day, po administered for 24 days2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID662222Antiproliferative activity against human Hep3B after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID662228Antiproliferative activity against human PLC/PRF/5 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1386574Inhibition of pig tubulin polymerization assessed as Vmax of tubulin polymerization at 10 uM after 60 mins turbidimetric analysis (Rvb = 27 +/- 2 milliOD/min)
AID1236550Antitumor activity against human H460 cells xenografted in athymic nu/nu mouse assessed as tumor regression at 550 mg/kg/day, po administered for 24 days2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID282691Cell cycle arrest in HEK293EBNA cells by accumulation at S phase cell at 50 uM relative to DMSO2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Identification of novel and improved antimitotic agents derived from noscapine.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1236522Cell cycle arrest in human HeLa cells assessed as accumulation at G1 phase after 24 hrs by FACS analysis (Rvb = 45.2%)2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID1236547Cytotoxicity against human H460 cells after 72 hrs2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID1386591Cytotoxicity against human MCF7 cells
AID1236526Binding affinity to tubulin (unknown origin)2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID282713Half life in mouse at 2 mg/kg, iv2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Identification of novel and improved antimitotic agents derived from noscapine.
AID1236536Antiproliferative activity against human A172 cells assessed as decrease in colony formation2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID1200928Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay2015European journal of medicinal chemistry, Mar-26, Volume: 93Fluoroalkane thioheterocyclic derivatives and their antitumor activity.
AID1763084Antibacterial activity against Staphylococcus aureus assessed as inhibition of bacterial growth2021Bioorganic & medicinal chemistry letters, 07-01, Volume: 43Antibacterial activity of noscapine analogs.
AID1236531Inhibition of tubulin polymerization in human HeLa cells assessed as polymeric tubulin level at 1 uM2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID662215Binding affinity to calf brain tubulin alpha/beta heterodimer assessed as increase in proton signal at 300 mM by STD NMR analysis2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID662237Cell cycle arrest in human SNU398 cells assessed as accumulation at sub-G1 phase at 2 uM after 24 hrs by FACS analysis (Rvb = 1.2%)2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1386579Effect on calcein-AM accumulation in human wild type MCF7 cells at 1 uM by fluorescence assay
AID662232Antiproliferative activity against human SNU423 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1236569Cytotoxicity against human A549 cells2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID1236541Cell cycle arrest in human TMZ-resistant U251 cells assessed as accumulation at G1 phase at 30 uM after 24 hrs by flow cytomtery analysis (Rvb = 47.53%)2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID1386590Cytotoxicity against human HeLa cells
AID249639Effect to arrest GI-phase on HEK 293 cells at 50 uM was determined2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
Discovery of S-phase arresting agents derived from noscapine.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID249636Effect to arrest S-phase on HEK 293 cells at 50 uM was determined2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
Discovery of S-phase arresting agents derived from noscapine.
AID1236533Inhibition of tubulin polymerization in human HeLa cells assessed as polymeric tubulin level at 100 uM2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID1236523Cell cycle arrest in human HeLa cells assessed as accumulation at S phase after 24 hrs by FACS analysis (Rvb = 12.9%)2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID1386563Binding affinity to recombinant P-gp cys-less mutant (unknown origin) in proteoliposomes assessed as increase in ATP hydrolysis rate after 40 mins by colorimetric assay
AID662224Antiproliferative activity against human HuH7 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID662230Antiproliferative activity against human SNU387 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1236542Cell cycle arrest in human TMZ-resistant U251 cells assessed as accumulation at S phase at 30 uM after 24 hrs by flow cytomtery analysis (Rvb = 33.05%)2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID282712Volume of distribution in mouse at 2 mg/kg, iv2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Identification of novel and improved antimitotic agents derived from noscapine.
AID662236Cell cycle arrest in human SNU398 cells assessed as accumulation at G2 phase at 2 uM after 24 hrs by FACS analysis (Rvb = 38.2%)2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1173390Antiproliferative activity against human HeLa cells after 72 hrs by MTS assay2014Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24
Synthesis and biological evaluation of novel biaryl type α-noscapine congeners.
AID1386573Cell cycle arrest in human PANC1 cells assessed as accumulation at G2/M phase at 10 uM after 18 hrs by Hoechst 33342 staining based FACS analysis (Rvb = 13.7%)
AID721753Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells at 20 uM after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1185192Inhibition of bovine brain tubulin assessed as rate of assembly preincubated for 15 mins by turbidimetry2014European journal of medicinal chemistry, Sep-12, Volume: 84Novel 9'-substituted-noscapines: synthesis with Suzuki cross-coupling, structure elucidation and biological evaluation.
AID662218Antiproliferative activity against human PLC/PRF/5 cells2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1236543Cell cycle arrest in human TMZ-resistant U251 cells assessed as accumulation at G2/M phase at 30 uM after 24 hrs by flow cytomtery analysis (Rvb = 19.42%)2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID721748Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells up to 500 uM after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1386592Terminal half life in human
AID721751Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1386576Antiproliferative activity against human MCF7 cells after 6 days by MTT assay
AID1386577Antiproliferative activity against human NCI/ADR-RES cells after 6 days by MTT assay
AID1236527Growth inhibition in human HeLa cells assessed as reduction of growth at 50 uM2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID282706Effect on cell growth in A549 cells by MTS assay2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Identification of novel and improved antimitotic agents derived from noscapine.
AID1173392Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay2014Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24
Synthesis and biological evaluation of novel biaryl type α-noscapine congeners.
AID282690Cell cycle arrest in HEK293EBNA cells by accumulation at G1 phase cell at 50 uM relative to DMSO2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Identification of novel and improved antimitotic agents derived from noscapine.
AID1236534Antitumor activity against rat C6 cells xenografted in mouse assessed as reduction of tumor volume relative to control2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID1386571Cell cycle arrest in human PANC1 cells assessed as accumulation at G1 phase at 10 uM after 18 hrs by Hoechst 33342 staining based FACS analysis (Rvb = 70.7%)
AID311934Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID282715AUC in mouse at 20 mg/kg, po2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Identification of novel and improved antimitotic agents derived from noscapine.
AID352600Antiproliferative activity against human HeLa cells at 34 uM after 24 hrs by sulforhodamine B assay2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
2,3-Disubstituted-1,4-naphthoquinones, 12H-benzo[b]phenothiazine-6,11-diones and related compounds: synthesis and biological evaluation as potential antiproliferative and antifungal agents.
AID1165121Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by methylene blue staining-based assay2014Bioorganic & medicinal chemistry letters, Oct-15, Volume: 24, Issue:20
Anti-tumor activity of novel biisoquinoline derivatives against breast cancers.
AID1236529Inhibition of tubulin polymerization in human HeLa cells assessed as shortening of microtubules at 50 uM2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID662241Cell cycle arrest in human PLC/PRF/5 cells assessed as accumulation at G1 phase at 2 uM after 24 hrs by FACS analysis (Rvb = 66.8%)2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID662217Antiproliferative activity against human SNU398 cells2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1200929Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay2015European journal of medicinal chemistry, Mar-26, Volume: 93Fluoroalkane thioheterocyclic derivatives and their antitumor activity.
AID1236539Cell cycle arrest in human U251 cells assessed as accumulation at S phase at 30 uM after 24 hrs by flow cytomtery analysis (Rvb = 18.08%)2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID662233Antiproliferative activity against human SNU449 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1386583Binding affinity to recombinant P-gp cys-less mutant (unknown origin) in proteoliposomes assessed as increase in ATP hydrolysis rate at 10'-9 to 10'-4 M after 40 mins by colorimetric assay relative to basal control
AID662227Antiproliferative activity against human JHH7 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1236532Inhibition of tubulin polymerization in human HeLa cells assessed as polymeric tubulin level at 10 uM2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID1165118Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by methylene blue staining-based assay2014Bioorganic & medicinal chemistry letters, Oct-15, Volume: 24, Issue:20
Anti-tumor activity of novel biisoquinoline derivatives against breast cancers.
AID721754Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID662242Cell cycle arrest in human PLC/PRF/5 cells assessed as accumulation at G2 phase at 2 uM after 24 hrs by FACS analysis (Rvb = 26.1%)2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1236540Cell cycle arrest in human U251 cells assessed as accumulation at G2/M phase at 30 uM after 24 hrs by flow cytomtery analysis (Rvb = 22.31%)2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID282711AUC in mouse at 2 mg/kg, iv2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Identification of novel and improved antimitotic agents derived from noscapine.
AID662229Antiproliferative activity against human SNU182 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1386581Inhibition of P-gp in human NCI/ADR-RES cells assessed as rate of calcein-AM accumulation at 1 uM by fluorescence assay
AID662219Antiproliferative activity against human SMMC7721 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1185194Displacement of [3H]colchicine from bovine brain tubulin assessed as rate of assembly at 500 uM after 10 mins by liquid scintillation counting2014European journal of medicinal chemistry, Sep-12, Volume: 84Novel 9'-substituted-noscapines: synthesis with Suzuki cross-coupling, structure elucidation and biological evaluation.
AID1236568Cytotoxicity against human HeLa cells2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID662235Cell cycle arrest in human SNU398 cells assessed as accumulation at G1 phase at 2 uM after 24 hrs by FACS analysis (Rvb = 55.8%)2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1185191Inhibition of bovine brain tubulin assessed as extent of assembly preincubated for 15 mins by turbidimetry2014European journal of medicinal chemistry, Sep-12, Volume: 84Novel 9'-substituted-noscapines: synthesis with Suzuki cross-coupling, structure elucidation and biological evaluation.
AID249643Effect to arrest G2/M-phase on HEK 293 cells at 50 uM was determined2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
Discovery of S-phase arresting agents derived from noscapine.
AID1236565Cell cycle arrest in human HeLa cells assessed as accumulation at G2/M phase by measuring 4N DNA content at 6.4 uM by flow cytometry2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID662225Antiproliferative activity against human JHH2 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID282714Clearance in mouse at 2 mg/kg, iv2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Identification of novel and improved antimitotic agents derived from noscapine.
AID1236564Antimitotic activity against human HeLa cells2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID282705Inhibition of tubulin polymerization2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Identification of novel and improved antimitotic agents derived from noscapine.
AID1236537Antiproliferative activity against human U251 cells assessed as decrease in colony formation2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID311932Inhibition of ASM in human H4 cells assessed as residual activity at 10 uM2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID1236570Cytotoxicity against human MCF7 cells2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID662220Antiproliferative activity against human MHCC97H after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1236530Inhibition of tubulin polymerization in human HeLa cells assessed as microtubules spent time in attenuated state at 50 uM2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID1675129Cytotoxicity against human MCF7 cells assessed as mortality at 20 uM after 48 hrs by MTT assay relative to control2020Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
Discovery of noscapine derivatives as potential β-tubulin inhibitors.
AID662243Cell cycle arrest in human PLC/PRF/5 cells assessed as accumulation at sub-G1 phase at 2 uM after 24 hrs by FACS analysis (Rvb = 1.4%)2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1200927Cytotoxicity against human SH-SY5Y cells after 48 hrs by MTT assay2015European journal of medicinal chemistry, Mar-26, Volume: 93Fluoroalkane thioheterocyclic derivatives and their antitumor activity.
AID1386582Ratio of nicardipine activity to test compound activity for inhibition of P-gp in human NCI/ADR-RES cells assessed as rate of calcein-AM accumulation
AID1386575Cytotoxicity against human Renal 1983 cells
AID282707Effect on cell growth in A549 cells by colony-forming assay2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Identification of novel and improved antimitotic agents derived from noscapine.
AID662231Antiproliferative activity against human SNU398 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1236525Induction of apoptosis in human HeLa cells after 24 hrs2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID662223Antiproliferative activity against human HepG2 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (482)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990183 (37.97)18.7374
1990's23 (4.77)18.2507
2000's67 (13.90)29.6817
2010's155 (32.16)24.3611
2020's54 (11.20)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 75.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index75.69 (24.57)
Research Supply Index6.27 (2.92)
Research Growth Index4.93 (4.65)
Search Engine Demand Index135.44 (26.88)
Search Engine Supply Index2.04 (0.95)

This Compound (75.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials16 (3.14%)5.53%
Reviews24 (4.71%)6.00%
Case Studies5 (0.98%)4.05%
Observational0 (0.00%)0.25%
Other465 (91.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase I Open Label Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma [NCT00912899]Phase 112 participants (Actual)Interventional2007-12-31Terminated(stopped due to Terminated early due to lack of clinical response.)
Phase I/II Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy [NCT00183950]Phase 1/Phase 212 participants (Actual)Interventional2000-03-31Terminated(stopped due to No funding)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]